The Overall Survival of Patients With Unresectable HCC in Real-life

Recruiting now

Conditions studied: Hepatocellular Carcinoma

In brief

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China). The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.

Key facts

Study ID

NCT03612726

Run by

Humanity & Health Medical Group Limited

People needed

5000

Starts

2018-07-16

Expected to finish

2025-12-31

Last updated by the study team

2025-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a diagnosis of unresectable hepatocellular carcinoma
• Able to comprehend and provide written informed consent in accordance with institutional guidelines.

You may not qualify if…

• Patients not willing to participate and/or give their written informed consent.

Where it is running

• Beijing 302 Hospital — Beijing, China (enrolling)
• Humanity & Health Medical Group Limited — Hong Kong, Hong Kong (enrolling)
• Tokyo University — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.